Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is listed today as Pyxis Oncology, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Pyxis Oncology, Inc., its revenue in fiscal 2025 came from these product and service lines: Sale of Royalty Rights $11.04 million (80%), Milestone Revenue $2.82 million (20%).
Annual report (SEC XBRL) · Dec 2025
Pyxis Oncology, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2021).
SEC Form D · Mar 2021
The industry group it chose in its notices: Other Health Care.
SEC Form D · Mar 2021
Products and services#
No products or services of Pyxis Oncology, Inc. are on record.
Investors#
5 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Bayer World Investments B.V. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Asset Management, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Global Healthcare Master Fund, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Private Healthcare Fund III LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| John L. Flavin | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2021) | SEC Form 3 |
Largest shareholders today
Institutions holding Pyxis Oncology, Inc. shares, as of Sep 30, 2026.
- GordonMD Global Investments LP$36 M12.99%
- BVF Inc/il$28 M9.89%
- Orbimed Advisors LLC$19 M6.99%
- Pfizer Inc$16 M5.88%
- RTW Investments, LP$15 M5.44%
- Laurion Capital Management LP$12 M4.17%
- Vanguard Capital Management LLC$9 M3.34%
- Longaeva Partners L.P.$5 M1.66%
- Heights Capital Management, Inc$3 M1.05%
- Wells Fargo & Company/mn$3 M0.93%
- BlackRock, Inc.$2 M0.87%
- Armistice Capital, LLC$2 M0.86%
- Empery Asset Management, LP$2 M0.84%
- Blue Owl Capital Holdings LP$2 M0.84%
- Palo Alto Investors LP$2 M0.72%
As of Sep 30, 2026
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Lara Sullivan | Executive officer | Mar 2021 |
| Robert Crane | Executive officer | Mar 2021 |
| David Steinberg | Executive officer | Jul 2019 |
| Christian Schetter | Director | Mar 2021 |
| Christopher O?Donnell | Director | Mar 2021 |
| David Steinberg | Director | Mar 2021 |
| Gotham Makker | Director | Mar 2021 |
| John Flavin | Director | Mar 2021 |
| Lara Sullivan | Director | Mar 2021 |
| Lucio Iannone | Director | Mar 2021 |
| Christoph Westphal | Director | Jul 2019 |
| Geeta Vemuri | Director | Jul 2019 |
| Jak Knowles | Director | Jul 2019 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.